Navigation Links
Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
Date:5/11/2011

0-1602 (international) five minutes prior to the start of the call and providing the passcode 55610905. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 69231212. The replay of the call will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Pacira's website at www.pacira.com. A replay of the webcast will be archived on the company's website for two weeks following the call.

About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture, and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA).  The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 28, 2011 for the review of the EXPAREL NDA.  EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.

About EXPAREL™EXPAREL is Pacira's proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam®, both of which are currently used separately in FDA-approved
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
2. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
3. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
4. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
5. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
6. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
10. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
11. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... -- MedicOne Medical Response, a leading provider emergency ... by Inc. Magazine as one of the fastest ... Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... companies with the largest revenue growth between 2010 ... two ambulance companies to make the list, achieved ...
(Date:9/15/2014)...  Catalist-listed QT Vascular Ltd. ("QT Vascular" or together ... of minimally invasive medical devices for the treatment of ... has enrolled the first European patients in the ENDURE ... have already been enrolled in this study with Dr. ... Auckland, New Zealand . ...
(Date:9/15/2014)... , Sept. 15, 2014  Over 200 patients, ... roof Saturday to learn, interact and participate in ... City,s first Lupus Trials Fair launched by the ... S.L.E. Lupus Foundation .  Attendees interacted directly ... -- sharing experiences, ideas and needs and learning ...
Breaking Medicine Technology:MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3
... ROCHESTER, N.Y., Sept. 8 VirtualScopics, Inc. (Nasdaq: ... for clinical trials, announced today that Ms. Molly Henderson, ... presenting a corporate overview at the Rodman & Renshaw ... City. Ms. Henderson,s presentation will be on Tuesday, September ...
... N.J., Sept. 8 Today every major pharmaceutical industry ... the future of pharma.  In an unprecedented move, they,re ... the big names in pharma.  All in one place. ... at the Pharma CI Conference & Exhibition at the ...
Cached Medicine Technology:VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference 2Pharmaceutical Industry Insiders, VIPs All Coming Together for Future of Pharma Market, Pharmaceutical Competitive Intelligence 2
(Date:9/15/2014)... York (PRWEB) September 15, 2014 Transvaginal ... Inc. continue to move forward in the federal multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... Final Order on September 10th that provides for the ... notes that none of the affected plaintiffs has objected ...
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- U.S. heart ... an electrocardiogram (ECG) when evaluating young people for underlying ... The American Heart Association and the American College ... more detailed personal and family medical history along with ... genetic or congenital (existing from birth) risks for sudden ...
(Date:9/15/2014)... the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer ... affecting both the front and the crown of their ... risk of developing aggressive prostate cancer (usually indicates a ... non-aggressive prostate cancer) later in life, compared to men ... other patterns of baldness and prostate cancer risk. The ...
(Date:9/15/2014)... 2014 - An estimated 8% of Americans will suffer ... during their lifetime. Brought on by an overwhelming or ... altered chemistry and physiology of the brain. Understanding how ... altered by PTSD is essential to developing effective interventions. ... at The University of Texas at Dallas published online ...
(Date:9/15/2014)... FL (PRWEB) September 15, 2014 The ... away from putting low-level offenders in jail and prison ... Group sees this shift as a positive change. , ... prescription drug and heroin abuse. According to an ... parties are calling for a shift away from using ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:EEG study findings reveal how fear is processed in the brain 2Health News:White House Shifts Policy on Drugs 2
... body of basic animal research and studies of abused ... for the hypothesis that individuals with particular genotypes are ... with the abuse of alcohol and other substances. ... assume that these genotypes identify people who are predestined ...
... Board of Directors Audit Committee Members and Complies with ... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... J. Wilson as vice president of finance and principal ... team. She brings over twenty years of finance ...
... of Suntan Lotions, Reducing Risk of Deadly Skin Cancer ... & Prevention MonthNEW YORK, April 29 The ... people avoid overexposure to harmful ultraviolet radiation from the ... all across America reduce the risk of skin cancer ...
... 23-month-old child in Texas; CDC warns more deaths are ... 23-month-old child in Texas has become the first U.S. ... officials said Wednesday morning. , Dr. Richard Besser, acting ... Prevention, confirmed the death. No other details on the ...
... Dr. Gordon Norman presents overview of US healthcare ... Federation of Health Plans Meeting in Boston- Noted ... value for its healthcare investment- Emphasized greater coordination ... resolve today,s healthcare challenges MARIETTA, Ga., April 29 ...
... & Mentally IllNEW YORK, April 29 May marks ... it, philanthropic-minded New Yorkers will raise money for Weston ... and physically disabled. As federal and state funding ... the current economy, supporters will raise funds amidst live ...
Cached Medicine News:Health News:Genetic risk for anxiety does not have to be destiny 2Health News:PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 3Health News:U.S. Reports First Swine Flu Death 2Health News:U.S. Reports First Swine Flu Death 3Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 2Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 3Health News:Weston United Celebrates Mental Health Month on May 19th 2
... The Driver Stent design, utilizing ... the limitations of stainless steel ... possible thinner struts, for unparalleled ... The Driver Coronary Stent Systemwith ...
... Guiding Catheter provides support to enhance ... under adverse conditions. It gives you ... to your destination in cardiac interventions. ... variety of clinical situations and the ...
... Catheters are intended for use ... applications. They provide a pathway ... as balloon dilatation catheters, guide ... may be introduced. These devices ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Medicine Products: